Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics cash
Cash and short-term investments held at the end of each period.
Halozyme Therapeutics's cash was $163.14M at Jun 30, 2026. For fiscal 2025 it was $133.82M, up 15.5% from the year before. Over ten years it grew 11.8% a year on average. The highest annual figure on record is $741.42M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.82M | +15.5% |
| FY2024 | Dec 31, 2024 | $115.85M | -2.1% |
| FY2023 | Dec 31, 2023 | $118.37M | -67.4% |
| FY2022 | Dec 31, 2022 | $363.29M | -51.0% |
| FY2021 | Dec 31, 2021 | $741.42M | +101.2% |
| FY2020 | Dec 31, 2020 | $368.51M | -12.6% |
| FY2019 | Dec 31, 2019 | $421.76M | +621.8% |
| FY2018 | Dec 31, 2018 | $58.44M | -65.5% |
| FY2017 | Dec 31, 2017 | $169.24M | +151.6% |
| FY2016 | Dec 31, 2016 | $67.26M | +53.6% |
| FY2015 | Dec 31, 2015 | $43.79M | -29.2% |
| FY2014 | Dec 31, 2014 | $61.89M | +126.2% |
| FY2013 | Dec 31, 2013 | $27.36M | -72.5% |
| FY2012 | Dec 31, 2012 | $99.50M | +90.0% |
| FY2011 | Dec 31, 2011 | $52.38M | -36.7% |
| FY2010 | Dec 31, 2010 | $82.76M | +22.7% |
| FY2009 | Dec 31, 2009 | $67.46M | +5.9% |
| FY2008 | Dec 31, 2008 | $63.72M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $163.14M | +163.7% |
| Q1 FY2026 | Mar 31, 2026 | $309.75M | +75.7% |
| Q4 FY2025 | Dec 31, 2025 | $133.82M | +15.5% |
| Q3 FY2025 | Sep 30, 2025 | $419.67M | +171.9% |
| Q2 FY2025 | Jun 30, 2025 | $61.86M | -67.1% |
| Q1 FY2025 | Mar 31, 2025 | $176.33M | +7.1% |
| Q4 FY2024 | Dec 31, 2024 | $115.85M | -2.1% |
| Q3 FY2024 | Sep 30, 2024 | $154.32M | -43.7% |
| Q2 FY2024 | Jun 30, 2024 | $187.86M | -15.1% |
| Q1 FY2024 | Mar 31, 2024 | $164.63M | -40.4% |
| Q4 FY2023 | Dec 31, 2023 | $118.37M | -67.4% |
| Q3 FY2023 | Sep 30, 2023 | $274.23M | +3.1% |
| Q2 FY2023 | Jun 30, 2023 | $221.17M | +5.4% |
| Q1 FY2023 | Mar 31, 2023 | $276.11M | -64.9% |
| Q4 FY2022 | Dec 31, 2022 | $363.29M | -51.0% |
| Q3 FY2022 | Sep 30, 2022 | $266.08M | -67.4% |
| Q2 FY2022 | Jun 30, 2022 | $209.86M | -72.2% |
| Q1 FY2022 | Mar 31, 2022 | $786.64M | +2.9% |
| Q4 FY2021 | Dec 31, 2021 | $741.42M | +101.2% |
| Q3 FY2021 | Sep 30, 2021 | $816.42M | +135.1% |
| Q2 FY2021 | Jun 30, 2021 | $755.81M | +95.8% |
| Q1 FY2021 | Mar 31, 2021 | $764.81M | +626.2% |
| Q4 FY2020 | Dec 31, 2020 | $368.51M | -12.6% |
| Q3 FY2020 | Sep 30, 2020 | $347.21M | +481.6% |
| Q2 FY2020 | Jun 30, 2020 | $385.95M | +471.4% |
| Q1 FY2020 | Mar 31, 2020 | $105.32M | +72.4% |
| Q4 FY2019 | Dec 31, 2019 | $421.76M | +621.8% |
| Q3 FY2019 | Sep 30, 2019 | $59.70M | +7.5% |
| Q2 FY2019 | Jun 30, 2019 | $67.54M | +21.3% |
| Q1 FY2019 | Mar 31, 2019 | $61.10M | -38.0% |
| Q4 FY2018 | Dec 31, 2018 | $58.44M | -65.5% |
| Q3 FY2018 | Sep 30, 2018 | $55.52M | -66.3% |
| Q2 FY2018 | Jun 30, 2018 | $55.67M | -51.5% |
| Q1 FY2018 | Mar 31, 2018 | $98.51M | -14.5% |
| Q4 FY2017 | Dec 31, 2017 | $169.24M | +151.6% |
| Q3 FY2017 | Sep 30, 2017 | $164.90M | +167.2% |
| Q2 FY2017 | Jun 30, 2017 | $114.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $115.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $67.26M | – |
| Q3 FY2016 | Sep 30, 2016 | $61.71M | – |
See a number that looks wrong?